Suppression of prostate cancer in a transgenic rat model via γ-tocopherol activation of caspase signaling

Prostate

Volumn 69, Issue 6, 2009, Pages 644-651

  Takahashi, Satoru ^a   Takeshita, Kentaro ^a   Seeni, Azman ^a,e   Sugiura, Satoshi ^a   Tang, Mingxi ^a   Sato, Shin Ya ^a   Kuriyama, Hiroki ^b   Nakadate, Masao ^b   Abe, Koichi ^c   Maeno, Yoshitaka ^d   Nagao, Masataka ^d,f   Shirai, Tomoyuki ^a  

^a Department of Experimental Pathologyand Tumor Biology ^*  (Japan)

^b Tama Biochemical Co Ltd   (Japan)

^c EISAI CO LTD   (Japan)

^d NAGOYA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICAL SCIENCES   (Japan)

^e SCHOOL OF HEALTH SCIENCES   (Malaysia)

^f HIROSHIMA UNIVERSITY   (Japan)

Author keywords

tocopherol; Chemoprevention; Prostate cancer; Transgenic rat model

Indexed keywords

CASPASE; CASPASE 3; CASPASE 7; ESTRADIOL; GAMMA TOCOPHEROL; TESTOSTERONE; ACID PHOSPHATASE; ACID PHOSPHATASE TARTRATE RESISTANT ISOENZYME; ANTIOXIDANT; CERAMIDE; ISOENZYME; TARTRATE-RESISTANT ACID PHOSPHATASE; TOCOPHEROL;

ANIMAL EXPERIMENT; ANIMAL TISSUE; ARTICLE; BODY WEIGHT; CONTROLLED STUDY; DIET; DOSE RESPONSE; ENZYME ACTIVATION; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; IMMUNOCHEMISTRY; MALE; NONHUMAN; ORGAN WEIGHT; PRIORITY JOURNAL; PROSTATE CANCER; QUANTITATIVE ANALYSIS; RAT; SIGNAL TRANSDUCTION; TRANSGENIC RAT; WEIGHT GAIN; ADENOCARCINOMA; ANIMAL; BLOOD; GENETICS; HUMAN; METABOLISM; MOUSE; PROSTATE TUMOR; TRANSGENIC ANIMAL;

ACID PHOSPHATASE; ADENOCARCINOMA; ANIMALS; ANIMALS, GENETICALLY MODIFIED; ANTIOXIDANTS; CERAMIDES; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; GAMMA-TOCOPHEROL; HUMANS; ISOENZYMES; MALE; MICE; PROSTATIC NEOPLASMS; RATS; TOCOPHEROLS;

EID: 65549106418     PISSN: 02704137     EISSN: 10970045     Source Type: Journal    
DOI: 10.1002/pros.20915     Document Type: Article

References (36)

1. Parkin DM, Bray FI, Devesa SS. Cancer burden in the year 2000. The global picture. Eur J Cancer 2001;37:S4-S66.
2. Jemal A, Murray T, Ward E, Samuels A, Tiwari RC, Ghafoor A, Feuer EJ, Thun MJ. Cancer statistics, 2005. CA Cancer J Clin 2005;55:10-30.
3. Franceschi S, La Vecchia C. Cancer epidemiology in the elderly. Crit Rev Oncol Hematol 2001;39:216-226. (Pubitemid 32743430)
4. Cunha GR, Donjacour AA, Cooks PS, Mee S, Bigsby RM, Higgins SJ, Sugimura Y. The endocrinology and developmental biology of the prostate. Endocr Rev 1987;8:338-362.
5. Denis LJ, Griffiths K. Endocrine treatment in prostate cancer. Semin Surg Oncol 2000;18:52-74. (Pubitemid 30036120)
6. Gronberg H. Prostate cancer epidemiology. Lancet 2003;361:859-864. (Pubitemid 36331852)
7. Nelson WG, De Marzo AM, Isaacs WB. Prostate cancer. N Engl J Med 2003;349:366-381. (Pubitemid 36886244)
8. Shirai T, Asamoto M, Takahashi S, Imaida K. Diet and prostate cancer. Toxicology 2002;181-182:89-94. (Pubitemid 36015678)
9. Heinonen OP, Albanes D, Virtamo J, Taylor PR, Huttunen JK, Hartman AM, Haapakoski J, Malila N, Rautalahti M, Ripatti S, Maenpaa H, Teerenhovi L, Koss L, Virolainen M, Edwards BK. Prostate cancer and supplementation with α-tocopherol and β-carotene: Incidence and mortality in a controlled trial. J Natl Cancer Inst 1998;90:440-446.
10. Helzlsouer KJ, Huang H-Y, Alberg AJ, Hoffman S, Burke A, Norkus EP, Morris JS, Comstock GW. Association between α-tocopherol, γ-tocopherol, selenium, and subsequent prostate cancer. J Natl Cancer Inst 2000;92(24):2018-2023. (Pubitemid 32045898)
11. Huang H-Y, Alberg AJ, Norkus EP, Hoffman SC, Comstock GW, Helzlsouer KJ. Prospective study of antioxidant micronutrients in the blood and the risk of developing prostate cancer. Am J Epidemiol 2003;157:335-344. (Pubitemid 36193936)
12. Nomura AM, Stemmermann GN, Lee J, Craft NE. Serum micronutrients and prostate cancer in Japanese Americans in Hawaii. Cancer Epidemiol Biomarkers Prev 1997;6:487-491. (Pubitemid 27295226)
13. Weinstein SJ, Wright ME, Pietinen P, King I, Tan C, Taylor PR, Virtamo J, Albanes D. Serum α-tocopherol and γ-tocopherol in relation to prostate cancer risk in a prospective study. J Natl Cancer Inst 2005;97:396-399. (Pubitemid 40425958)
14. Asamoto M, Hokaiwado N, Cho YM, Takahashi S, Ikeda Y, Imaida K, Shirai T. Prostate carcinomas developing in transgenic rats with SV40 T antigen expression under probasin promoter control are strictly androgen dependent. Cancer Res 2001;61:4693-4700. (Pubitemid 32691878)
15. Cho YM, Takahashi S, Asamoto M, Suzuki S, Inaguma S, Hokaiwado N, Shirai T. Age-dependent histopathological findings in the prostate of probasin/SV40 T antigen transgenic rats: Lack of influence of carcinogen or testosterone treatment. Cancer Sci 2003;94:153-157.
16. Said MM, Hokaiwado N, Tang M, Ogawa K, Suzuki S, Ghanem HM, Esmat AY, Asamoto M, Refaie FM, Shirai T. Inhibition of prostate carcinogenesis in probasin/SV40 T antigen transgenic rats by leuprorelin, a luteinizing hormone-releasing hormone agonist. Cancer Sci 2006;97:459-467. (Pubitemid 43811586)
17. Cho YM, Takahashi S, Asamoto M, Suzuki S, Tang T, Shirai T. Suppressive effects of antiandrogens, finasteride and flutamide on development of prostatic lesions in a transgenic rat model. Prostate Cancer Prost Dis 2007;10:378-383. (Pubitemid 350238088)
18. Seeni A, Takahashi S, Takeshita K, Tang M, Sugiura S, Sato SY, Shirai T. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac J Cancer Prev 2008;9:7-14.
19. Tang MX, Ogawa K, Asamoto M, HokaiwadoN, Seeni A, Suzuki S, Takahashi S, Tanaka T, Ichikawa K, Shirai T. Protective effects of citrus nobiletin and auraptene in transgenic rats developing adenocarcinoma of the prostate (TRAP) and human prostate carcinoma cells. Cancer Sci 2007;98:471-477. (Pubitemid 46566174)
20. Soeda S, Iwata K, Hosoda Y, Shimeno H. Daunorubicin attenuates tumor necrosis factor-α-induced biosynthesis of plasminogen activator inhibitor-1 in human umblical vein endothelial cells. Biochem Biophys Acta 2001;1538:234-241. (Pubitemid 32402246)
21. Galli F, Stabile AM, Betti M, Conte C, Pistilli A, Rende M, Floridi A, Azzi A. The effect of α- and γ-tocopherol and their carboxyethyl hydroxychroman metabolites on prostate cancer cell proliferation. Arch Biochem Biophys 2004;423(1):97-102. (Pubitemid 38198218)
22. Gysin R, Azzi A, Visarius T. γ-Tocopherol inhibits human cancer cell cycle progression and cell proliferation by down-regulation of cyclins. FASEB J 2002;16(14):1952-1954.
23. Jiang Q, Wong J, Fyrst H, Saba JD, Ames BN. γ-Tocopherol or combinations of vitamin E forms induce cell death in human prostate cancer cells by interrupting sphingolipid synthesis. Proc Natl Acad Sci USA 2004;101(51):17825-17830. (Pubitemid 40051971)
24. Yoshikawa S, Morinobu T, Hamamura K, Hirahara F, Iwamoto T. The effect of γ-tocopherol administration on α-tocopherol levels and metabolism in humans. Eur J Clin Nutr 2005;59:900-905. (Pubitemid 41195205)
25. Stone WL, Papas AM. Tocopherols and the etiology of colon cancer. J Natl Cancer Inst 1997;89:1006-1014. (Pubitemid 27327865)
26. Christen S, Woodall AA, Shigenaga MK, Southwell-Keely PT, Duncan MW, Ames BN. γ-Tocopherol traps mutagenic electrophiles such as NOx and complements α-tocopherol: Physiological implications. Proc Natl Acad Sci USA 1997;94:3217-3222.
27. Cooney RV, Franke AA, Harwood PJ, Hatch-Pigott V, Custer LJ, Mordan LJ. γ-Tocopherol detoxification of nitrogen dioxide: Superiority to α-tocopherol. Proc Natl Acad Sci USA 1997;90:1771-1775.
28. Hensley K, Benaksas EJ, Bolli R, Comp P, Grammas P, Hamdheydari L, Mou S, Pye QN, Stoddard MF, Wallis G. New perspectives on vitamin E: γ-tocopherol and carboxyethylhydroxychroman metabolites in biology and medicine. Free Rad Biol Med 2004;36(1):1-15.
29. Jiang Q, Ames BN. γ-Tocopherol, but not α-tocopherol, decreases proinflammatory eicosanoids and inflammation damage in rats. FASEB J 2003;17(8):816-822. (Pubitemid 36538656)
30. Jiang Q, Elson-Schwab I, Courtemanche C, Ames BN. γ-Tocopherol and its major metabolite, in contrast to α-tocopherol, inhibit cyclooxygenase activity in macrophages and epithelial cells. Proc Natl Acad Sci USA 2000;97(21):11494-11499.
31. Investigators THaH-TT. Effects of long-term vitamin E supplementation on cardiovascular events and cancer. JAMA 2005;293:1338-1347.
32. Lee I-M, Cook NR, Gaziano JM, Gordon D, Ridker PM, Manson JE, Hennekens CH, Buring JE. Vitamin E in the primary prevention of cardiovascular disease and cancer. JAMA 2005; 294:56-65.
33. Handelman GJ, Machlin LJ, Fitch K, Weiter JJ, Dratz EA. Oral α-tocopherol supplements decrease plasma γ-tocopherol levels in humans. J Nutr 1985;115:807-813.
34. Li D, Saldeen T, Romeo F, Mehta JL. Relative effects of α- and γ-tocopherol on low-density lipoprotein oxidation and superoxide dismutase and nitric oxide synthase activity and protein expression in rats. J Cardiovasc Pharmacol Ther 1999;4:219-226. (Pubitemid 29526529)
35. Mahabir S, Coit D, Liebes L, Brady MS, Lewis JJ, Roush G, Nestle M, Fry D, Berwick M. Randomized, placebo-controlled trial of dietary supplementation of α-tocopherol on mutagen sensitivity levels in melanoma patients: A pilot trial. Melanoma Res 2002;12:83-90.
36. White E, Kristal AR, Shikany JM, Wilson AC, Chen C, Mares- Perlman JA, Masaki KH, Caan BJ. Correlates of serum α- and γ-tocopherol in the Women's Health Initiative. Ann Epidemiol 2001;11:136-144. (Pubitemid 32054780)